arrow
P

Pilar Retamar

CSIC
H指数:27
被引数:5,153

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

How to use novel antimicrobials beyond official indications: an expert consensus

如何使用官方适应症之外的全新抗菌药物:一项专家共识

2025-12-010
PRE
An international Delphi survey on priorities in antimicrobial resistant infections therapeutic research: a preliminary study of MePRAM project

关于抗菌耐药性感染治疗研究优先事项的国际德尔菲调查:MePRAM项目的初步研究

2025-11-060
OAAI
Examining tailoring as an implementation strategy for reducing healthcare-associated infections across European acute care hospitals (REVERSE): study protocol for a hybrid type 2 effectiveness-implementation trial

将"量身定制"作为减少欧洲急性护理医院相关性感染的实施策略(REVERSE):一项混合类型2效果-实施试验的研究方案

2025-10-160
OAAI
Development and validation of a predictive mortality scoring model for bloodstream infections due to Escherichia coli in the PROBAC cohort

基于PROBAC队列的由大肠杆菌引起的血流感染死亡风险预测评分模型的开发与验证

2025-07-230
OA
Effectiveness of oral step-down therapy and early oral switch for bloodstream infections caused by Enterobacterales: A post hoc emulation trial of the SIMPLIFY trial

肠杆菌科细菌血流感染中口服降级疗法和早期口服转换的疗效:SIMPLIFY试验的后续模拟试验

2025-07-010
OAAI
Association of microbiological factors with mortality in Escherichia coli bacteraemia presenting with sepsis/septic shock: a prospective cohort study

微生物因素与脓毒症/脓毒性休克大肠杆菌菌血症死亡率的关系: 一项前瞻性队列研究

2024-08-010
OA
Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial

抗假单胞菌 β-内酰胺类药物结构化降阶梯治疗肠杆菌血流感染的有效性和安全性 (SIMPLIFY): 一项开放标签、多中心、随机试验

2024-04-016
PRE
Antibiotic use and outcome in patients with negative blood cultures, a new target population for antimicrobial stewardship interventions: A prospective multicentre cohort (NO-BACT)
2024-02-010
OAAI
Ten Issues for Updating in Community-Acquired Pneumonia: An Expert Review
2023-10-307
OAAI
Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: a post hoc analysis of the FOREST randomized trial
2023-06-016
OAAI
Autoantibodies against type I IFNs in patients with critical influenza pneumonia

重症流感肺炎患者中针对I型ifn的自身抗体

2022-09-1663
OAAI
Risk Factors and Predictive Score for Bacteremic Biliary Tract Infections Due to Enterococcus faecalis and Enterococcus faecium: a Multicenter Cohort Study from the PROBAC Project
2022-08-315
OAAI
Pseudomonas aeruginosa Community-Onset Bloodstream Infections: Characterization, Diagnostic Predictors, and Predictive Score Development-Results from the PRO-BAC Cohort
2022-05-244
OA
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)

欧洲临床微生物学和传染病学会 (ESCMID) 治疗由多重耐药革兰氏阴性杆菌引起的感染的指南 (由欧洲重症监护医学会认可)

2022-04-01475
OA
Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pseudomonas aeruginosa Pneumonia
2022-03-299
OAAI